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Background: Metformin and the thiazolidinediones (TZDs) may have a protective effect against the development
of lung cancer.
Methods: Patients with diabetes mellitus (DM) were identified from the electronic medical records of the Cleveland
Clinic. Diabetics with lung cancer were identified then verified by direct review of their records. Control subjects
were matched with cancer subjects 1:1 by date of birth, sex, and smoking history. The frequency and duration of
diabetic medication use was compared between the groups. The cancer characteristics were compared between
those with lung cancer who had and had not been using metformin and/or a TZD.
Results: 93,939 patients were identified as having DM. 522 lung cancers in 507 patients were confirmed. The
matched control group was more likely to have used metformin and/or a TZD (61.0% vs. 41.2%, p < 0.001 for any
use; 55.5% vs. 24.6%, p < 0.001 for >24 months vs. 0–12 months). In the group with lung cancer, those who had
used metformin alone had a different histology distribution than those who received neither metformin nor a TZD,
were more likely to present with metastatic disease (40.8% vs. 28.2%, p = 0.013), and had a shorter survival from the
time of diagnosis (HR 1.47, p < 0.005).
Conclusions: The use of metformin and/or the TZDs is associated with a lower likelihood of developing lung
cancer in diabetic patients. Diabetics who develop lung cancer while receiving metformin may have a more
aggressive cancer phenotype.
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Lung cancer is the leading cause of cancer related mor-
tality worldwide. Individuals at risk for developing lung
cancer can be identified by clinical epidemiologic factors
[1-4]. Recently, molecular predictors of the risk of devel-
oping lung cancer have also been sought [5-7]. The only
successful means of modifying one’s risk for developing
lung cancer is the avoidance of causative exposures, par-
ticularly cigarette smoking [8]. Attempts at developing
chemopreventive strategies have met with little success
to date. When lung cancer is diagnosed, it is often in an
advanced stage. Available treatment has a significant im-
pact on outcomes, however, the overall success of treat-
ment remains poor. Advances in the fields of lung* Correspondence: mazzonp@ccf.org
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reproduction in any medium, provided the orcancer chemoprevention and therapy have the potential
to reduce lung cancer related mortality.
Patients with diabetes mellitus (DM) often have clin-
ical risk factors for the development of cancer. Suggested
links in the biology of DM and cancer include hypergly-
cemia driving malignant cell growth, the insulin and
insulin-like growth factor axis leading to cell survival
and mitogenesis, and alterations in inflammatory cyto-
kines leading to suppression of antitumor immunity
[9,10]. An epidemiologic link between an increased inci-
dence of various cancers in diabetics, as well as a poorer
prognosis for cancer survival amongst diabetics, has
been suggested [9,10]. Studies assessing the impact of
DM on lung cancer prognosis have yielded variable
results [11].
Diabetes treatments may influence the risk of develop-
ing cancer and the prognosis of cancer when it develops.
There is epidemiologic and pathophysiologic evidenceal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nediones (TZDs) may have cancer suppressing effects
[12,13]. The aims of the current study were to determine
if the frequency of metformin and/or TZD use differs
between diabetic patients who develop lung cancer and
those who do not; and to determine if there are differ-
ences in the presentation and outcomes of diabetic
patients with lung cancer who have used metformin
and/or a TZD compared to those who have not.
Methods
Study design and data collection
The current study received institutional review board
approval from the Cleveland Clinic. This was a retro-
spective, case–control study. An electronic medical rec-
ord search of the Cleveland Clinic Health System
patients identified subjects with a recorded diagnosis of
DM. Data automatically extracted from the electronic
record (when recorded) included the diabetic patient’s
date of birth, sex, tobacco history, diagnosis of lung can-
cer, medications being used, date of first use of medica-
tions, body mass index (BMI) measures, hemoglobin
A1c (HbA1c) values, and whether the subject was living
or deceased. Categories of medication use included in
the analysis were metformin and/or a TZD vs. neither,
metformin without a TZD vs. neither (labeled metformin
alone), and a TZD without metformin vs. neither (la-
beled TZD alone). Insulin and sulfonylurea use was also
documented.
For each subject labeled as having a diagnosis of lung
cancer in the medical record, the diagnosis was con-
firmed through a direct review of the documentation
within their record. Additional data was extracted from
the records of those subjects confirmed as having lung
cancer, including the date of lung cancer diagnosis, hist-
ology of the cancer, stage at presentation, survival from
the date of diagnosis, and details of medication use
(type and dates). Lung cancer subjects were considered
to have used metformin or a TZD only if the use pre-
dated the diagnosis of lung cancer. Survival data was
supplemented by use of the Social Security Death Index
when necessary.
Control subjects were randomly selected from those
who were not labeled as having lung cancer. Control
subjects were matched to lung cancer subjects 1:1 based
on sex, date of birth (+/− 5 years), and tobacco history
when available for the cancer subject (current, former,
or never; then pack years +/− 10). When tobacco history
was not available for the cancer subject, the control was
selected to be a former smoker with a moderate number
of pack-years smoked. Eleven lung cancer patients did
not have their smoking status documented (current,
former, or never). The demographic and cancer charac-
teristics of these 11 were compared to the remainder ofthe lung cancer patients. There was no difference in any
parameter. In addition, data was analyzed both with
these 11 (and their matched controls) and without these
11 (and their matched controls) included. There was no
difference in any outcome described, thus we chose to
include data from the entire group. Additional data col-
lected on the control subjects included details of medi-
cation use (type and dates). Control subjects use of
metformin or a TZD was analyzed first when defined as
use prior to the lung cancer diagnosis of their matched
case, and separately when defined as use at any time.
The electronic medical record was available from 2001
through the time of completion of the record review
6/2011. All records available for each patient within
this timeframe were reviewed to obtain the above in-
formation. The diagnosis of lung cancer could have oc-
curred at any time during the patient’s life, as long as
it had been documented definitively within their med-
ical record. The year of diagnosis was available for all
cancers (522 of 522, 100%). The date of diagnosis was
available for 459 of 522 cancers (87.9%). When the
date was not available the midpoint of the year was used.
The range of dates of diagnosis was 1978 – 7/28/2010. 24
of the cancers (5.0%) were diagnosed prior to 1995, when
the first of the medications in question became available.
Data was analyzed both with and without these 24
patients and their matched controls included. Results did
not differ between these analyses so we chose to present
data from the entire group. The duration of medication
use was taken as the date of first documented use to final
documented use. If the final documented use was at the
time of the last physician visit, the medication was con-
sidered to be used up to the point of the end of data col-
lection. Follow-up continued to the point of the last
patient visit encounter in the EMR. The SS Death Index
was accessed at the end of study data collection.
Statistical analysis
Continuous variables were assessed by Wilcoxon rank
sum tests. Categorical variables were compared using
chi-square and Fisher’s exact test where appropriate.
Univariate survival analysis was performed using the log
rank test with Kaplan-Meier curves. Cox regression was
used to assess the hazard ratio for survival in the group
with lung cancer after adjusting for statistically signifi-
cant factors. Conditional logistic regression including all
unmatched statistically significant factors, as well as
tobacco pack-years was used to assess the influence of
metformin and/or TZD use on the risk of developing
lung cancer. All analyses were performed with SAS 9.2
(Cary, NC, USA). For comparison between lung cancer
cases and matched controls, age was calculated at a fixed
point in time (1/1/1990) as matching was based on date
of birth. For comparison within the lung cancer group,
Table 2 Association between diabetic medication use and
a diagnosis of lung cancer
Lung
cancer
Control 1 Control 2 P-value
Metformin
and/or TZD
Any use 41.2 61.0 93.9 <0.001
>24 months 24.6 55.5 75.1 <0.001
Metformin alone Any use 25.0 30.3 49.5 <0.001
TZD alone Any use 6.5 10.5 9.9 <0.001
Insulin use 26.8 33.9 0.014
Sulfonylurea use 39.1 42.0 0.34
All numbers expressed as % of subjects taking the drugs listed in each
category. Control 1 = started the defined medication prior to the diagnosis of
lung cancer in the matched case, Control 2 = started the defined medication
either prior to or after the diagnosis of lung cancer in the matched case.
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nosis. BMI and HbA1c values used in comparisons were
the means of all available values for each study subject,
and the median value of the individual subjects mean
values for the groups being compared.
Results
Patient population
A total of 93,939 subjects with a diagnosis of DM were
identified from the electronic medical record search. Of
these, 66.4% of all subjects were listed as using metfor-
min and/or a TZD during their life. From the entire
group, 645 had a diagnosis of lung cancer listed in their
electronic record. Upon review of the electronic charts,
a total of 522 lung cancers in 507 subjects were con-
firmed. The lung cancer and control subjects were well
matched for the variables selected, except for tobacco
smoking status where unknown values in the lung can-
cer group were matched to controls with known values
(Table 1). The results of the following analysis did not
differ if those with missing smoking values (and their
matched controls) were excluded from the analysis. The
BMI of the lung cancer group was slightly lower than
the control group (28.7 kg/m2 vs. 30.6 kg/m2, p < 0.001).
The HbA1c levels of the lung cancer group were similar
to those of the control group (7.0 vs. 7.2, p = 0.17).
Association of Metformin and/or TZD Use with
lung cancer
Study subjects with lung cancer were less likely to be
using metformin and/or a TZD prior to their lung can-
cer diagnosis than their matched controls (41.2% vs.
61.0%, p < 0.001). Similarly, study subjects with lung can-
cer were less likely to be using metformin alone (without








56.2 (49.1, 61.6) 56.6 (49.7, 62.0) 0.39
Gender Female 38.9% 38.9% >0.99
Male 61.1% 61.1%




Pack-years 40 (25, 45) 35 (25, 45) 0.13
BMI 28.7 (25.1, 33.4) 30.6 (26.8, 35.5) <0.001
HbA1c 7.0 (6.3, 7.8) 7.2 (6.5, 7.8) 0.17
Age, pack-years, BMI, and HbA1C are listed as medians (25th, 75th percentiles).
Age is listed as of 1/1/1990 for comparison purposes since matching was
based on date of birth.
All subjects with known diabetes mellitus.subjects with lung cancer were less likely to be using
metformin and/or a TZD for more than 2 years duration
than their matched controls (24.6% vs. 55.5%, p < 0.001).
(Table 2) In a model including all factors statistically dif-
ferent and/or potentially not completely matched be-
tween the cancer and control groups (medication use,
BMI, HbA1C, and pack-years of smoking), only medica-
tion use was found to be associated with a lower odds of
developing lung cancer. The odds ratio (OR) and 95% CI
for metformin and/or TZD use is 0.47 (0.32-0.68,
p < 0.001), for metformin alone 0.48 (0.28-0.81,
p = 0.006), and for TZD alone 0.86 (0.4-1.85, p = 0.14).
Lung cancer patient population
In the group of study subjects who had a confirmed
diagnosis of lung cancer, those who were receiving met-
formin and/or a TZD were older than those who were
not (72.2 years vs. 68.3 years, p < 0.001). The two groups
had a similar sex distribution (% female 37.2 vs. 39.5,
p = 0.59). There was a suggestion of more active smokers
in the group with lung cancer who were receiving met-
formin and/or a TZD (18.8% vs. 11.2%, p = 0.099), but a
similar number of pack-years smoked was noted be-
tween the groups (median 36.5 vs. 40.0, p = 0.68). The
BMI was similar in those with lung cancer receiving
metformin and/or a TZD and those who were not (BMI
of 28.8 vs. 28.3, p = 0.60). The HbA1c was higher
in those receiving metformin and/or a TZD (HbA1c of
7.3 vs. 6.7, p < 0.001).
Lung cancer phenotype associations with metformin
and/or TZD Use
In the group of study subjects who had a confirmed
diagnosis of lung cancer, a statistically borderline differ-
ence was noted in the lung cancer histology distribution
between those who were and were not receiving metfor-
min and/or a TZD (Table 3). This relationship held true
for those receiving metformin alone (p = 0.014), but did
not reach significance for those receiving a TZD alone








Small cell 14.2 12.9 14.7 12.2
Adenocarcinoma 42.2 47.0 35.3 38.2
Squamous cell 23.4 23.5 26.5 19.4
Large cell 6.0 3.0 11.8 13.2
Non-small cell
unspecified
14.2 13.6 11.8 17.1
P-values: A. vs. D. 0.061, B. vs. D. 0.014, C. vs. D. 0.82.
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a TZD were more likely to present with metastatic dis-
ease (39.8% vs. 28.2%, p = 0.008). This relationship held
true for metformin alone (40.8% vs. 28.2%, p = 0.013) but
not TZDs alone (31.3% vs. 28.2%, p = 0.72). In univariate
analysis, the survival of those with lung cancer receiving
metformin and/or a TZD was shorter than those who
were not (p < 0.001). This relationship held true for those
receiving metformin alone (p < 0.001), but not a TZD
alone (p = 0.21) (Figure 1). In multivariate analysis, the
HRs for survival, after correction for stage and age, in
those receiving metformin and/or a TZD was 1.22 (0.96-
1.55, p = 0.30), in those receiving metformin alone was
1.47 (1.12-1.92, p = 0.005), and in those receiving a TZD
alone was 1.04 (0.65-1.66, p = 0.87) (Table 4).
Discussion
Our study has identified an association between the use
of metformin and/or a TZD and a lower likelihood of
developing lung cancer in patients with DM. In addition,
those who developed lung cancer while receiving met-
formin were more likely to present with metastatic dis-
ease, had a lower survival rate (after correction for stage
and age), and had a different histology distribution than
those who were not receiving either of these drugs.
For an association to be considered causal, several cri-
teria need to be considered. Ideally, there should be a
strong association that increases as the exposure
increases; the exposure should occur before the disease
appears; the association should not conflict significantly
with what is already known of the disease; the associ-
ation should be biologically plausible; and the associ-
ation cannot be due to any source of error.
The association between the development of lung can-
cer and the use of metformin and/or a TZD reported
here was strong (control group was 1.5 times more likely
to have used these medications, OR 0.47) and increased
with greater exposure duration (control group was 2.3
times more likely to have used one of these medications
for longer than 24 months). All exposures in the cancer
group occurred prior to the diagnosis of cancer.
The associations identified in this study are consistent
with prior reports. A population based study of 11876diabetics included 923 subjects with a cancer. Those
with cancer were less likely to be receiving metformin
than those without (36.4% vs. 39.7%) [14]. In a study of
10309 diabetics, cancer related mortality was reported in
3.5% of metformin users, 5.9% of sufonylurea users, and
5.8% of insulin users [15]. A report of 22,621 females
with DM using oral glucose lowering drugs included 305
women with breast cancer. Only 17 of the women with
breast cancer had used metformin > 5 years, as compared
to 120 matched controls (OR 0.44) [16]. In a neoadju-
vant chemotherapy trial for breast cancer 24% of 68 sub-
jects with DM receiving metformin had a complete
response to therapy, whereas only 8% of 87 who were
not taking metformin, and 16% on non-diabetics did
[17]. Metformin use in a mouse model of lung cancer
development was shown to reduce the lung tumor bur-
den by 53-72% [18]. Finally, in a cohort trial of 87,678
newly diagnosed diabetics over age 40, 1,371 lung can-
cers developed over a 7 year timeframe. A 33% reduction
in lung cancer risk was seen among TZD users after ad-
justment for covariates [19].
The associations reported in this study are biologically
plausible. Metformin impairs mitochondrial ATP pro-
duction inducing an energy stress at the cellular level.
AMP-activated protein kinase (AMPK) is a key cellular
energy sensor. During energy stresses, when the ratio of
AMP:ATP increases, AMP binds to AMPK, allowing its
activation through phosphorylation by the constituitively
active upstream kinase LKB1. Activation of AMPK leads
to a shift from energy depleting synthetic metabolic
pathways to energy conserving metabolic processes; to
an increase in P53 activity, resulting in cell cycle arrest
at the G1/S checkpoint, apoptosis, and activation of
autophagy pathways; and to a decrease in mTOR activity
resulting in a decrease in protein synthesis, cell growth,
and a reduction in survivin levels [20-26]. AMPK has a
direct link with cell proliferation during the M-phase of
the cell cycle, represses mitosis-gene families, and cytokin-
esis genes [27]. In LKB1 and P53 mutant tumors there
may be an inability to compensate for metformin induced
energy stresses [25]. Additional potentially protective
actions of metformin include decreases in circulating insu-
lin levels, as well as inhibition of phosphorylation of IGF-
1R/IR, Akt, ERK, and mTOR [12]. It is possible that lung
cancers that develop in the face of metformin use are less
sensitive to energy stresses or bypass the pathways influ-
enced by metformin use, resulting in a more aggressive
cancer phenotype and the observation of increased meta-
static disease, and shorter survival. Thiazolidinediones are
ligands for PPAR-gamma, a transcription factor highly
expressed in cancer cell lines [28]. Exposure to TZDs
in vitro leads to cell cycle arrest, apoptosis, and/or redif-
ferentiation through PPAR-gamma dependent and inde-
pendent actions [29,30].
Figure 1 Survival analysis of patients with DM and lung cancer. A. Those receiving metformin and/or a TZD versus those who were not. B.
Those receiving metformin alone versus those receiving neither metformin nor a TZD. C. Those receiving a TZD alone versus those receiving
neither metformin nor a TZD.
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Table 4 Hazard ratios for survival in diabetic patients
with lung cancer based on their use of metformin and/or
a TZD, corrected for stage at presentation and age
HR (95% CI) P-value
Metformin and/or TZD vs. neither 1.22 (0.96, 1.55) 0.30
Metformin alone vs. neither 1.47 (1.12, 1.92) 0.005
TZD alone vs. neither 1.04 (0.65, 1.66) 0.87
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to sources of error can never be discounted in retrospect-
ive epidemiologic studies. Attempts to minimize the po-
tential influence of random errors and biases were made
by including all of the identified lung cancer subjects, hav-
ing a relatively large sample size, by directly reviewing
each of the study subjects’ medical records, and by match-
ing controls based on known and identifiable risk factors.
An effect-cause error was avoided by insuring medication
use prior to lung cancer diagnosis was documented. The
greatest remaining potential for error is the presence of a
confounding variable. The level of glucose control and the
BMI are potential confounders. The level of glucose con-
trol, as estimated by the HbA1c values, did not differ be-
tween cancer and control subjects, or within the groups of
lung cancer subjects who were and were not receiving
metformin and/or a TZD. The BMI of the control group
was slightly higher than the cancer group. This is in keep-
ing with other reports suggesting a potential protective ef-
fect of obesity on the risk of developing lung cancer [4]. It
is difficult to know if the lower BMI in the cancer group
represents the protective effect of obesity or if it is related
to weight loss from the cancer itself. There was no differ-
ence in the BMI of the cancer subjects who were and
those who were not receiving metformin and/or a TZD.
These factors were not found to be associated with lung
cancer risk or survival when assessed with multivariate
statistics. There has been a secular trend in lung cancer
histology in the United States. An influence of this trend,
combined with an increased use of the studied DM medi-
cations over time, on the association of histology distribu-
tion with medication use cannot be discounted. When
only subjects who developed their lung cancer after 1995
were included in the analysis (480 of 507) the results were
identical to those presented in the results section (results
not shown). Other unknown confounders, such as the po-
tential selection of DM medication based on symptoms or
co-morbidities that are associated with lung cancer, cannot
be controlled for with this study design. Overall, the
strength and consistency of the associations identified sup-
port the findings despite the design.
Conclusions
The use of the biguanide metformin and/or the TZDs is
associated with a reduction in the risk of developinglung cancer. Diabetics who develop lung cancer while
receiving metformin may have a more aggressive cancer
phenotype. The role of these drugs as chemopreventive
agents deserves further study.
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